The role of beta-blockers after myocardial infarction in patients with LVEF is under debate, after research was unveiled at the ESC Congress.

Increasing plasma potassium levels can improve outcomes in patients with CVD at high risk of ventricular arrhythmias, study ...

Dr Stefania Angela Di Fusco and Prof. Furio Colivicchi share key highlights, cardiovascular research and guidelines from ESC Congress 2025.

Prof Nirmalie Wiratunga discusses the innovative iCARE Health Hub using AI to improve follow-up care for AYA cancer survivors.

Using TNF-alpha inhibitors (TNFi) in people with severe psoriasis is more effective at preventing psoriatic arthritis (PsA) than narrow-band UVB (nbUVB) phototherapy over almost 10 years, new research ...

Patients with psoriasis who show an early response to treatment with the biologics risankizumab or guselkumab are more likely to respond well to treatment over the long term, a new study has found.

A new study highlights the risks of atopic dermatitis flare-ups after discontinuing the use of dupilumab. Nearly half of patients who stopped taking the systemic biologic treatment, for reasons other ...

Metastatic uveal melanoma may be a rare disease, but it poses a major clinical challenge, with limited systemic treatment options and a strong predilection for liver metastases. This expert commentary ...

A new inherited DNA repair deficiency syndrome, which increases a patient’s risk of developing blood cancer but also leaves them susceptible to DNA damage from chemotherapy, has been identified by a ...

The use of technology and artificial intelligence-enabled digital tools for the diagnosis and management of health conditions will be expanded to include cardiology and respiratory services, as well ...

Genomic data and transformative technology, including the expansion of the NHS App, are central to the NHS 10-year plan for a Neighbourhood Health Service, the Government has announced. Prime Minister ...

Patients who have been hospitalised for acute pancreatitis after using glucagon-like peptide-1 (GLP-1) receptor agonists are being urged to report this through the Yellow Card scheme as part of an ...